1. Home
  2. MKTW vs BOLD Comparison

MKTW vs BOLD Comparison

Compare MKTW & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MarketWise Inc.

MKTW

MarketWise Inc.

HOLD

Current Price

$17.58

Market Cap

39.7M

Sector

Technology

ML Signal

HOLD

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.45

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MKTW
BOLD
Founded
1999
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
39.7M
36.5M
IPO Year
2020
2024

Fundamental Metrics

Financial Performance
Metric
MKTW
BOLD
Price
$17.58
$1.45
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
$20.00
$4.00
AVG Volume (30 Days)
24.9K
407.6K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
10.33%
N/A
EPS Growth
1183.33
32.47
EPS
2.31
N/A
Revenue
$512,403,000.00
N/A
Revenue This Year
$1.52
N/A
Revenue Next Year
$4.55
N/A
P/E Ratio
$7.56
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.65
$0.96
52 Week High
$21.74
$1.78

Technical Indicators

Market Signals
Indicator
MKTW
BOLD
Relative Strength Index (RSI) 55.90 57.09
Support Level $16.06 $1.08
Resistance Level $20.62 $1.55
Average True Range (ATR) 0.87 0.09
MACD -0.04 -0.01
Stochastic Oscillator 77.84 58.04

Price Performance

Historical Comparison
MKTW
BOLD

About MKTW MarketWise Inc.

Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: